Catalyst Event

Natera Inc (NTRA) · Other

From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)

5/29/2026, 12:00:00 AM

OtherSentiment: Positive

Scheduled to announce a collaboration with Diakonos Oncology for a Phase I/II clinical trial on 2026-05-29; Low importance due to expected >1% price impact from clinical collaboration scheduled.

Korean Translation

2026년 5월 29일, 불응성 흑색종 임상시험을 위해 Diakonos Oncology와 협력할 예정임. 임상 협력으로 1% 이상의 주가 영향이 예정됨.

Related Recent Events

View Full Timeline